Pritelivir

Summary

Pritelivir (CHEMBL4069597) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including genital herpes and herpes labialis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 7
• Chemistry: 402.5 Da · C18H18N4O3S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4069597
Name	Pritelivir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	491941
Molecular formula	C18H18N4O3S2
Molecular weight	402.5
InChIKey	IVZKZONQVYTCKC-UHFFFAOYSA-N

SMILES: CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N

IUPAC name: N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide

Also known as: AIC-090093, AIC-316, AIC090093, Aic316, AIC316, Pritelivir, PRITELIVIR, C0088799

Parent form; salt/anhydrous children: CHEMBL4082238, CHEMBL4562772, CHEMBL5194635

Patent coverage: 106 distinct patent families (325 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 299 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Carbonic anhydrase 2, Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 9, Carbonic anhydrase 5B, mitochondrial, Carbonic anhydrase 5A, mitochondrial.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CA2	7.89	Ki	12.8	nM	CHEMBL_ACT_18044894
CA12	7.11	Ki	77.2	nM	CHEMBL_ACT_18044971
CA9	7.09	Ki	81	nM	CHEMBL_ACT_18044994
CA1	6.49	Ki	323	nM	CHEMBL_ACT_18044985
CA5B	6.41	Ki	389	nM	CHEMBL_ACT_18044936
CA5A	6.32	Ki	474	nM	CHEMBL_ACT_18044915
CA2	5.7	IC50	2000	nM	CHEMBL_ACT_24719277

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
genital herpes	2	MONDO:0005770	EFO:0007282
herpes labialis	2	MONDO:0043653	MONDO:0043653
herpes simplex infectious disease	1	MONDO:0004609	EFO:1002022

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03073967	PHASE3	COMPLETED	Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
NCT01047540	PHASE2	COMPLETED	Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
NCT01658826	PHASE2	TERMINATED	Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
NCT02871492	PHASE2	COMPLETED	Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
NCT05513625	PHASE1	COMPLETED	Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir
NCT05671029	PHASE1	COMPLETED	Thorough QT/QTc of Pritelivir in Healthy Subjects
NCT05844436	Not specified	AVAILABLE	Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).